Ultrasmall silica nanoparticles directly ligate the T cell receptor complex

Component: Nanoparticles; Description: Amorphous ultrasmall silica nanoparticles (USSN); median volume diameter 3.6 nm; negative surface charge (~−20 mV at pH 7.1); gradually dissolves to orthosilicic acid [Si(OH)₄]

Component: Size Controls; Description: • 5.1 nm USSN (less active)<br>• 7.8 nm USSN (less active)<br>• Larger silica nanoparticles (DV0.5 = 14.1 ± 1.4 nm; inactive)<br>• Dissolved silica [Si(OH)₄] (inactive)

Component: Cell Types; Description: • Primary human PBMCs (CD4⁺ and CD8⁺ T cells) from healthy donors (n=23)<br>• Jurkat CD4⁺ T cell line (competent TCR)<br>• Karpas-299 CD4⁺ T cell line (lacks competent TCR complex)

Component: Activation Readouts; Description: CD69, CD25 expression (flow cytometry); IL-2 secretion (ELISA); Zap70 and LAT phosphorylation (Western blot); CFSE dilution (proliferation)

Component: Costimulatory Agents; Description: Anti-CD28 antibody; phorbol-12,13-dibutyrate (PdBu); ionomycin

Component: Controls; Description: Anti-CD3/CD28 antibodies; SEB (superantigen); dissolved silica; larger silica nanoparticles; hydrogen peroxide (positive control for phosphorylation)

Parameter: USSN Preparation; Details: Dilution of alkaline sodium silicate in water; pH adjustment with HCl; aged >12 h; sterile-filtered (0.2 μm) prior to use

Parameter: Cell Culture; Details: PBMCs isolated from leukocyte cones; rested 2 h in RPMI + 10% FBS; USSN at 800 μM [Si]; 24 h incubation for activation markers

Parameter: Competitive Binding Assays; Details: PBMCs treated with USSN (5 min); fluorescent antibodies for TCRαβ, CD3ε, CD4, CD8; flow cytometry; % positive cells and MFI

Parameter: Phosphorylation Studies; Details: Jurkat cells or enriched T cells; USSN treatment (0.2-6 h); Western blot (pZap70, pLAT); vinculin loading control

Parameter: IL-2 Secretion; Details: 24 h culture; ELISA (R&D Systems); USSN ± PdBu (0.5 μg/mL) ± ionomycin (0.2 μg/mL)

Parameter: Proliferation; Details: CFDA-SE dilution; 72 h culture; USSN ± anti-CD3/CD28; flow cytometry

Parameter: Molecular Modeling; Details: Human TCR:CD3 complex from solved structures and homology models; electrostatic potential (Blues); USSN represented as pseudoatoms (3.6, 5, 8, 15 nm)

Parameter: Replicates; Details: 3-23 donors/independent replicates; mean ± SD

Parameter: Statistical Tests; Details: Paired t-test; two-way ANOVA; P < 0.05 significant

Analysis Category: Nanoparticle Characterization; Methods: DLS (Zetasizer NanoZS): size, zeta potential; Molybdic acid dissolution assay (400 nm absorbance); ICP-OES (Si concentration); Ultrafiltration (3 kDa MWCO)

Analysis Category: Flow Cytometry; Methods: Beckman Coulter CYAN ADP; antibodies: CD3-VioGreen, CD3-PE, CD4-PE/FITC, CD8-APC/APC-Cy7, CD25-FITC/APC-H7, CD69-APC, αβTCR-FITC, γδTCR-FITC, 7-AAD viability stain; 400,000 events; Summit software; gating strategy in SI Appendix

Analysis Category: Western Blot; Methods: 4-12% bis-Tris gels; PVDF membrane; primary antibodies: pZap70 (Tyr319), pLAT, vinculin; HRP-secondary; ECL Plus; GeneGnome XRQ; GeneTools band volume integration

Analysis Category: Molecular Modeling; Methods: Modeler v9.17 (homology modeling); PyMOL (structural visualization); Blues (electrostatic surfaces); MolProbity (stereochemistry)

Analysis Category: ELISA; Methods: IL-2 (R&D Systems, #DY202) per manufacturer's protocol

Cell Type: CD4⁺ T cells (n=23); Control (%): Low; USSN (800 μM) (%): Significantly increased; Fold Increase: p < 0.05

Cell Type: CD8⁺ T cells (n=23); Control (%): Low; USSN (800 μM) (%): Significantly increased; Fold Increase: p < 0.05

Cell Type: Karpas-299 (no TCR); Control (%): Low; USSN (800 μM) (%): No activation; Fold Increase: NS

Cell Type: 4% BSA (n=3); Control (%): Low; USSN (800 μM) (%): No inhibition; Fold Increase: NS (albumin did not block)

Antibody Target: TCRαβ; % Positive Cells (Control): 100%; % Positive Cells (USSN): ~10-20%; Effect: Almost entirely inhibited

Antibody Target: CD3ε; % Positive Cells (Control): 100%; % Positive Cells (USSN): ~10-20%; Effect: Almost entirely inhibited

Antibody Target: CD4; % Positive Cells (Control): ~65%; % Positive Cells (USSN): ~60%; Effect: Minimal change

Antibody Target: CD8; % Positive Cells (Control): ~35%; % Positive Cells (USSN): ~30%; Effect: Minimal change

Antibody Target: Inhibition duration; % Positive Cells (Control): 5 min: maximal; % Positive Cells (USSN): 4 h: almost none; Effect: Mirrors USSN dissolution

Particle: 3.6 nm USSN; T Cell Activation: Strong; Antibody Binding Inhibition: Strong

Particle: 5.1 nm USSN; T Cell Activation: Decreased; Antibody Binding Inhibition: Decreased

Particle: 7.8 nm USSN; T Cell Activation: Very low; Antibody Binding Inhibition: Very low

Particle: 14 nm silica; T Cell Activation: None; Antibody Binding Inhibition: None

Particle: Dissolved silica [Si(OH)₄]; T Cell Activation: None; Antibody Binding Inhibition: None

Particle: Conclusion; T Cell Activation: <8 nm required; Antibody Binding Inhibition: Size-dependent

Parameter: Electropositive patches; Finding: Present on TCRα and CD3γε; interface between domains

Parameter: 3.6-5 nm particles; Finding: Can access electropositive patches (spatially feasible)

Parameter: 8-15 nm particles; Finding: Sterically hindered by cell membrane; cannot access patches

Parameter: Binding site; Finding: Likely CD3 subunits (not TCRαβ), as γδ TCR also responded

Parameter: γδTCR antibody binding; Control: 100%; USSN: Inhibited

Parameter: CD69 expression; Control: Low; USSN: Significantly increased

Parameter: CD25 expression; Control: Low; USSN: Significantly increased

Parameter: Conclusion; Control: USSN bind CD3 subunits, not TCR αβ/γδ variable domains

Protein: pZap70 (Jurkat); Control: Low; USSN (0.2-1 h): Markedly increased; Positive Control (H₂O₂): Increased

Protein: pZap70 (primary T cells); Control: Low; USSN (0.2-1 h): Increased; Positive Control (H₂O₂): -

Protein: pLAT (primary T cells); Control: Low; USSN (0.2-1 h): Significant increase; Positive Control (H₂O₂): -

Protein: Kinetics; Control: -; USSN (0.2-1 h): Peak: 0.2-1 h; Positive Control (H₂O₂): Decreased by 2-6 h (particle dissolution)

Treatment: USSN alone; IL-2 (pg/mL): No significant increase

Treatment: Ionomycin alone; IL-2 (pg/mL): Low

Treatment: PdBu alone; IL-2 (pg/mL): Low

Treatment: USSN + ionomycin; IL-2 (pg/mL): Modest increase

Treatment: USSN + PdBu; IL-2 (pg/mL): Significant increase

Treatment: Ionomycin + PdBu; IL-2 (pg/mL): Significant increase (positive control)

Treatment: Conclusion; IL-2 (pg/mL): USSN provide primary signal only (calcium/NFAT pathway); no secondary signal (PKC/MAPK pathway)

Condition: USSN alone; CD4⁺ T Cell Proliferation: No proliferation; CD8⁺ T Cell Proliferation: No proliferation

Condition: Anti-CD3 alone; CD4⁺ T Cell Proliferation: Modest; CD8⁺ T Cell Proliferation: Modest

Condition: USSN + anti-CD28; CD4⁺ T Cell Proliferation: Significant proliferation; CD8⁺ T Cell Proliferation: Significant proliferation

Condition: Anti-CD3 + anti-CD28; CD4⁺ T Cell Proliferation: Significant (positive control); CD8⁺ T Cell Proliferation: Significant

Condition: Conclusion; CD4⁺ T Cell Proliferation: Costimulation required for full proliferation; CD8⁺ T Cell Proliferation: -

1. In vitro only: All experiments performed with cultured cells; no in vivo data on T cell activation, biodistribution, or therapeutic efficacy.

2. Partial agonist only: USSN provide primary TCR signal but require costimulation (anti-CD28 or PdBu) for IL-2 secretion and proliferation; this limits their use as stand-alone T cell activators.

3. Rapid dissolution: USSN dissolve within hours in culture medium, limiting the duration of TCR engagement and signaling (phosphorylation decreased by 2-6 h).

4. No in vivo extrapolation: The authors explicitly state: "Our current data do not allow extrapolation to in vivo oral or parenteral applications."

5. Potential for off-target effects: USSN may interact with other cell surface proteins beyond TCR:CD3; the study focused primarily on T cells but did not extensively characterize effects on other immune cells.

6. Mechanism of specificity unclear: While the study demonstrates TCR:CD3 binding, the exact molecular contacts (which CD3 subunits, specific amino acid residues) are not definitively identified.

7. Cell line specificity: Karpas-299 lacks a competent TCR complex, but the study did not confirm that USSN do not affect other signaling pathways in this cell line.

8. Donor variability: CD69 expression varied across 23 donors; while statistically significant, the magnitude of response may be donor-dependent.

9. No comparison to other ultrasmall particles: The study did not test whether other inorganic ultrasmall nanoparticles (e.g., gold, iron oxide) have similar T cell-activating properties.

10. Serum protein interactions: While 4% BSA did not inhibit USSN activity, other serum proteins or in vivo protein coronas may differ and affect activity.

11. pH dependence: USSN surface charge is pH-dependent; effects in different physiological compartments were not assessed.

12. Theoretical modeling limitations: The molecular models are based on solved structures and homology models, but the exact orientation of USSN binding and the number of particles per TCR complex were not experimentally determined.

Report prepared based on the published PNAS article. For full experimental details, supplementary figures, and complete references, please refer to the original publication.